|
T4081 |
MPTP hydrochloride
|
MPTP-hydrochloride |
Apoptosis
,
Dopamine Receptor
|
|
MPTP hydrochloride is a precursor of MPP+, a dopamine neurotoxin with blood-brain barrier permeability. MPTP hydrochloride is toxic to dopaminergic neurons, which can lead to Parkinson's disease, and is widely used in th... |
|
T9722 |
YTX-465
|
|
Stearoyl-CoA Desaturase (SCD)
|
|
YTX-465 is an inhibitor of both stearoyl-CoA desaturase(IC50s = 39 nM) and Ole1 (IC50s = 30.4 μM). |
|
T16115 |
MLi-2
|
|
LRRK2
|
|
MLi-2 is a structurally novel, highly potent, and selective LRRK2 kinase inhibitor with central nervous system activity. MLi-2 exhibits exceptional potency in a purified LRRK2 kinase assay in vitro (IC50 = 0.76 nM), a ce... |
|
T8322 |
BL-918
|
|
Autophagy
|
|
BL-918 is a potent activator of UNC-51-like kinase 1 (ULK1) with an EC50 of 24.14 nM. |
|
T2344 |
LY 344864
|
LY344864 |
5-HT Receptor
|
|
LY 344864, a specifc receptor agonist, is an affinity of 6 nM (Ki) at the recently cloned 5-HT1F receptor. |
|
T10492 |
BD-AcAc 2
|
Ketone Ester |
Reactive Oxygen Species
|
|
|
|
T7155 |
JH-II-127
|
|
LRRK2
|
|
JH-II-127 is an orally inhibitor of leucine-rich repeat kinase 2 (LRRK2). It inhibits WT LRRK2, G2019S LRRK2 and A2016T LRRK2 (IC50s = 6.6, 2.2, and 47.7 nM, respectively), |
|
T22830 |
GYY4137
|
GYY 4137 morpholine salt |
Others
|
|
GYY4137 (GYY 4137 morpholine salt) is a novel water-soluble and slow releasing H2S donor with vasodilator and antihypertensive activity. GYY4137 also exhibits anti-inflammatory and anticancer activity. |
|
T0059 |
Diphenylpyraline hydrochloride
|
4-Diphenylmethoxy-1-methylpiperidine hydrochloride |
Histamine Receptor
|
|
Diphenylpyraline hydrochloride (4-Diphenylmethoxy-1-methylpiperidine hydrochloride) is used in the treatment of Parkinsonism.It is a first-generation antihistamine with anticholinergic effects, functions as a dopamine re... |
|
T8702 |
SKF-83566
|
|
Dopamine Receptor
,
5-HT Receptor
,
AChR
|
|
SKF-83566 is a blood-brain permeable and orally active antagonist of D1-like dopamine receptor and a weaker competitive 5-HT2 receptor antagonist with Ki of 11 nM |
|
T0267 |
Zonisamide
|
AD 810,CI 912 |
Calcium Channel
,
Sodium Channel
,
Carbonic Anhydrase
|
|
Zonisamide (AD 810), a sulfonamide anticonvulsant, is approved for use as an adjunctive treatment in adults with partial-onset seizures. It may inhibit a carbonic anhydrase although this is not one of the main mechanisms... |
|
T0378 |
Oxybuprocaine hydrochloride
|
Risedronic Acid,Oxybuprocaine HCl |
Sodium Channel
|
|
Oxybuprocaine hydrochloride (Oxybuprocaine HCl), a local anesthetic, is used especially in otolaryngology and ophthalmology. |
|
T7196 |
HG-10-102-01
|
|
LRRK2
|
|
HG-10-102-01 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 of 20.3 nM). |
|
T12352 |
Oxidopamine hydrochloride
|
6-Hydroxydopamine hydrochloride,6-OHDA hydrochloride |
Mitophagy
,
Dopamine Receptor
,
Autophagy
|
|
Oxidopamine hydrochloride (6-Hydroxydopamine hydrochloride) is an neurotransmitter dopamine antagonist. |
|
T12352L |
Oxidopamine hydrobromide
|
6-Hydroxydopamine hydrobromide,6-OHDA hydrobromide |
Mitophagy
,
Dopamine Receptor
,
Autophagy
|
|
Oxidopamine hydrobromide (6-OHDA hydrobromide) is a neurotransmitter dopamine antagonist. |
|
T4659 |
ELN484228
|
|
Others
|
|
ELN484228 is a α-synuclein blocker. α-synuclein is a key protein in Parkinson’s disease. |
|
T28861 |
ST-1535
|
|
Adenosine Receptor
|
|
ST 1535 is a potent and orally active antagonist of A2A adenosine receptor with antiparkinsonian activity and antitremorigenic effects. ST 1535 exhibits the potential for the research of Parkinson’s disease. |
|
T13048 |
SynuClean-D
|
SC-D |
Others
|
|
SynuClean-D (SC-D) is an α-synuclein aggregation inhibitor preventing fibril propagation, disrupting mature amyloid fibrils, and abolishing the degeneration of dopaminergic neurons in an animal model of Parkinson’s disea... |
|
T22103 |
ML-193
|
CID 1261822 |
Cannabinoid Receptor
|
|
ML-193 (CID 1261822) is a potent and selective GPR55 antagonist( IC50 : 221 nM). It shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2, and can improve the motor and the sensorimotor deficits of Parkin... |
|
T11599 |
Ibiglustat (L-Malic acid)
|
Ibiglustat L-Malic acid,GZ402671 (L-Malic acid),Venglustat (L-Malic acid),SAR402671 (L-Malic acid) |
Transferase
|
|
Ibiglustat (L-Malic acid) (Ibiglustat L-Malic acid) is a selective, brain-penetrant, and allosteric inhibitor of glucosylceramide synthase. Ibiglustat (L-Malic acid) can be used in studies about PD Parkinson’s disease, S... |
|
T35028 |
Valiglurax
|
VU2957,VU 0652957,VU 2957,VU-0652957,VU0652957,VU-2957 |
GluR
|
|
Valiglurax (VU2957), also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties acro... |
|
T67729 |
UCM-1306
|
|
Dopamine Receptor
|
|
UCM-1306 is a potent and orally active allosteric modulator (PAM) of human dopamine D1 receptor. UCM-1306 could increase the maximal effect of endogenous dopamine (DA) both in human and mouse D1 receptors. UCM-1306 could... |
|
T13049 |
Synucleozid
|
NSC 377363 |
Others
|
|
Synucleozid is a potent the SNCA mRNA inhibitor that encodes α-synuclein protein (IC50=1.5 μM), has the potential for the investigation of Parkinson’s disease. |
|
T29133 |
VU0410150
|
VU-0410150,VU 0410150 |
|
|
VU0410150, a pyrrylarylsulfone containing compound, has been found to be a mGluR4-positive allosteric modulator and has been evaluated as a potential drug for the treatment of Parkinson’s disease. |
|
T11448 |
GOAT-IN-1
|
|
Others
|
|
|
|
T13049L |
Synucleozid hydrochloride (502139-01-7 free base)
|
Synucleozid hydrochloride,NSC 377363 hydrochloride |
Others
|
|
Synucleozid hydrochloride is a potent the SNCA mRNA inhibitor that encodes α-synuclein protein (IC50=1.5 μM), has the potential for the investigation of Parkinson’s disease. |
|
T61347 |
D4R antagonist-1
|
|
|
|
D4R Antagonist-1, characterized by its potent and selective antagonistic action against D4 receptors with an IC50 value of 6.87 μM, holds potential for Parkinson’s disease research [1]. |
|
T78671 |
Glucocerebrosidase-IN-1 hydrochloride
|
|
Glucosidase
|
|
Glucocerebrosidase-IN-1 (compound 11a) hydrochloride is a potent, selective GCase (glucocerebrosidase) inhibitor with IC50 and Ki values of 29.3 μM and 18.5 μM, respectively. It is utilized in the research of Gaucher dis... |
|
T75876 |
α-Conotoxin PIA TFA
|
|
|
|
α-Conotoxin PIA TFA, targeting nicotinic acetylcholine receptor (nAChR) subtypes with α6 and α3 subunits, acts as an antagonist. This compound shows promise for research into Parkinson’s disease and schizophrenia [1]. |
|
T60573 |
MAO-B-IN-15
|
|
|
|
MAO-B-IN-15 is a selective inhibitor of MAO-B that forms π-π interaction with Tyr 326 residue (IC 50 = 13.5 μM) which can be used in Parkinson’s disease research[1]. |
|
T40999 |
NMDA receptor antagonist 2
|
|
|
|
NMDA receptor antagonist 2 is a highly potent and orally active NR2B subtype-selective antagonist of the N-methyl-D-aspartate (NMDA) receptor. It exhibits remarkable binding affinities, with an IC50 of 1.0 nM and a Ki va... |
|
T60650 |
MAO-B-IN-13
|
|
|
|
MAO-B-IN-13 (compound 12a) is a highly potent, reversible and blood-brain barrier (BBB) penetrant MAO-B inhibitor (IC50 = 10 nM). MAO-B-IN-13 shows neuroprotective and antioxidant activity which can be used in Parkinson’... |
|
T12662 |
(Rac)-BL-918
|
|
Others
|
|
(Rac)-BL-918 is the racemate of BL-918. BL-918 is a potent activator of UNC-51-like kinase 1 (ULK1) with an EC50 of 24.14 nM, inducing cytoprotective autophagy for Parkinson’s disease treatment [1]. |
|
T80151 |
α-Synuclein 4554W
|
|
|
|
α-Synuclein 4554W, previously identified through intracellular library screening, is an inhibitor of α-Synuclein (aSyn) aggregation and its associated toxicity. This compound, comprising GIVNGVKA sequences, effectively r... |
|
T37533 |
DOPAL
|
|
|
|
DOPAL is an aldehyde product of the oxidative deamination of dopamine by monoamine oxidase.[1] It can be further oxidized to 3,4-dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenase (ALDH) and, to a lesser extent... |
|
T62054 |
D4R antagonis-2
|
|
|
|
D4R antagonist-2 is a potent and selective D4R antagonist (IC50= 6.52 μM). D4R antagonist-2 displays favorable in vitro PK parameters and exhibits good brain penetration. D4R antagonist-2 has the research potential in Pa... |
|
T60824 |
Dyrk1A-IN-3
|
|
|
|
Dyrk1A-IN-3 (Compound 8b) is a highly selective inhibitor of dual-specificity tyrosine-regulated kinase 1A (DYRK1A). Dyrk1A-IN-3 has high binding affinity of DYRK1A with an IC 50 of 76 nM. Dyrk1A-IN-3 can be used in neur... |
|
T73530 |
2-PAT
|
|
|
|
2-PAT, analogous to Rasagiline and Selegiline, functions as a reversible MAO-A inhibitor, exhibiting an IC50 of 0.721 µM, and acts as an inactivator of MAO-B with an IC50 value of 14.6 µM. This compound shows promise for... |
|
T60658 |
HMAO-B/MB-COMT-IN-2
|
|
|
|
hMAO-B/MB-COMT-IN-2 is a dual inhibitor of MAO-B/MB-COMT with IC 50s of 4.27 μΜ and 2.69 μΜ for hMAO-B and MB-COMT, respectively. hMAO-B/MB-COMT-IN-2 protects cells from oxidative damage that can be used in the neurodege... |
|
T60489 |
HMAO-B/MB-COMT-IN-1
|
|
|
|
hMAO-B/MB-COMT-IN-1 is a dual MAO-B/MB-COMT inhibitor with IC50s of 2.5 μΜ for hMAO-B and 3.84 μΜ for MB-COMT. hMAO-B/MB-COMT-IN-1 protects cells from oxidative damage that can be used in neurodegeneration disease resear... |
|
T60353 |
Glucocerebrosidase-IN-1
|
|
|
|
Glucocerebrosidase-IN-1 (compound 11a) is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC 50 of 29.3 μM and a K i of 18.5 μM. Due to GCase involvement in pathological disorders consequent to enzym... |
|
T83328 |
4A7C-301
|
|
|
|
4A7C-301, a Nurr1 agonist, exhibits potent neuroprotective effects in vitro and markedly mitigates neuropathological abnormalities while enhancing motor and olfactory functions in male mouse models with AAV2-mediated α-s... |
|
T72452 |
AChE/BChE/MAO-B-IN-2
|
|
|
|
AChE/BChE/MAO-B-IN-2 is a potent inhibitor of the enzymes AChE, BChE, and MAO-B, with IC50 values of 48.2 nM, 83.9 nM, and 31.2 nM, respectively. It exhibits significant antioxidant activity and is applicable in Parkinso... |
|
T60656 |
Monoamine Oxidase B inhibitor 1
|
|
|
|
Monoamine Oxidase B inhibitor 1 is a potent, reversible, orally active and selective monoamine oxidase B (MAO-B) inhibitor (IC50 = 0.02 nM) that can across the blood-brain barrier (BBB). Monoamine Oxidase B inhibitor 1 s... |
|
T60806 |
Monoamine Oxidase B inhibitor 2
|
|
|
|
Monoamine Oxidase B inhibitor 2 is a potent, reversible, orally active and selective inhibitor of monoamine oxidase B (MAO-B) (IC50 = 1.33 nM) which can across the blood-brain barrier (BBB). Monoamine Oxidase B inhibitor... |
|
T72314 |
α-Synuclein inhibitor 8
|
|
|
|
α-Synuclein inhibitor 8 effectively impedes α-Synuclein aggregation and disaggregation with an IC50 of 2.5 µM, demonstrating substantial reduction in neuronal inclusion formation, which contributes to reparative effects ... |
|
T74638 |
XL01126
|
|
|
|
XL01126, a potent degrader of LRRK2, exhibits DC50 values of 14 nM (G2019S LRRK2) and 32 nM (WT LRRK2), respectively. It has the ability to cross the blood-brain barrier, making it a viable degrader probe for Parkinson’s... |
|
T72280 |
PBT434 methanesulfonate
|
|
|
|
PBT434 methanesulfonate is an orally active, potent α-synuclein aggregation inhibitor with the ability to cross the blood-brain barrier. Acting as an iron chelator, it modulates transcellular iron trafficking, inhibits i... |
|
T83875 |
HUP-55
|
|
|
|
HUP-55 is a prolyl endopeptidase inhibitor with an IC50 of 5 nM, shown to mitigate α-synuclein dimerization in Neuro2a cells, stimulate autophagy in HEK293 cells, and lower hydrogen peroxide-evoked reactive oxygen specie... |
|
T36176 |
AMK (hydrochloride)
|
|
|
|
AMK is an active metabolite of the neurohormone melatonin .1,2,3,4It is formed from melatoninviathe metabolic intermediate AFMK that is then deformylated by catalase or formamidase.5,6AMK scavenges singlet oxygenin vitro... |
